MiRNAs as novel biomarkers in the management of prostate cancer

Clinical Chemistry and Laboratory Medicine

Volumn 55, Issue 5, 2017, Pages 715-736

  Filella, Xavier ^a   Foj, Laura ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

biomarkers; miR 141; miR 21; miR 375; miRNAs; prostate cancer

Indexed keywords

MICRORNA; MICRORNA 141; MICRORNA 21; MICRORNA 375; TUMOR MARKER;

BIOGENESIS; CANCER DIAGNOSIS; CANCER GENETICS; CANCER STEM CELL; CANCER TISSUE; DIAGNOSTIC VALUE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; REVIEW; RNA ANALYSIS; SERUM; URINALYSIS; BLOOD; GENE EXPRESSION REGULATION; GENETICS; MALE; PATHOLOGY; PROSTATE TUMOR; URINE;

BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS;

EID: 85017246029     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-1073     Document Type: Review

References (128)

1. Melichar B. PSA, PCA3 and the philosophy of prostate cancer management. Clin Chem Lab Med 2013;51:707-12.
2. Filella X, Foj L. Emerging biomarkers in the detection and prognosis of prostate cancer. Clin Chem Lab Med 2015;53:963-73.
3. Stephan C, Jung K, Ralla B. Current biomarkers for diagnosing of prostate cancer. Future Oncol 2015;11:2743-55.
4. Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes 2013;20:204-9.
5. Alcover J, Filella X. Identification of candidates for active surveillance: should we change the current paradigm? Clin Genitourin Cancer 2015;13:499-504.
6. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011;12:861-74.
7. Sun T, Ye H, Wu C-L, Lee G-S, Kantoff PW. Emerging players in prostate cancer: long non-coding RNAs. Am J Clin Exp Urol 2014;2:294.
8. . Filella X, Foj L, Milà M, Augé JM, Molina R, Jiménez W. PCA3 in the detection and management of early prostate cancer. Tumour Biol 2013;34:1337-47.
9. Lee RC, Feinbaum RL, Ambros V. The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.
10. Griffiths-Jones S. miRBase: the microRNA sequence database. Methods Mol Biol Clifton NJ 2006;342:129-38.
11. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108:5003-8.
12. Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, et al. Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol 2014;191:1132-8.
13. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012;7:e30679.
14. Cheng L, Sun X, Scicluna BJ, Coleman BM, Hill AF. Characterization and deep sequencing analysis of exosomal and non- exosomal miRNA in human urine. Kidney Int 2014;86:433-44.
15. Weber JA, Baxter DH, Zhang S, Huang DY, How Huang K, Jen Lee M, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733-41.
16. Lan H, Lu H, Wang X, Jin H. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. BioMed Res Int 2015;2015:1-17.
17. Whale AS, Huggett JF, Cowen S, Speirs V, Shaw J, Ellison S, et al. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res 2012;40:e82.
18. Ma J, Li N, Guarnera M, Jiang F. Quantification of plasma miRNAs by digital PCR for cancer diagnosis. Biomark Insights 2013;8:127-36.
19. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9.
20. Fletcher CE, Dart DA, Bevan CL. Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers. Endocr Relat Cancer 2014;21:R409-29.
21. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
22. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
23. Søkilde R, Vincent M, Møller AK, Hansen A, Høiby PE, Blondal T, et al. Efficient identification of miRNAs for classification of tumor origin. J Mol Diagn 2014;16: 106-15.
24. Sun Y, Zhang K, Fan G, Li J. Identification of circulating microRNAs as biomarkers in cancers: what have we got? Clin Chem Lab Med 2012;50:2121-6.
25. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. Comparing the microRNA spectrum between serum and plasma. PLoS One 2012;7:e41561.
26. Kim D-J, Linnstaedt S, Palma J, Park JC, Ntrivalas E, Kwak-Kim JY, et al. Plasma components affect accuracy of circulating cancerrelated microRNA quantitation. J Mol Diagn 2012;14:71-80.
27. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One 2011;6:e24145.
28. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila Pa) 2012;5:492-7.
29. Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wrang Teilum M, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 2013;59:S1-6.
30. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova- Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 2008;105:10513-8.
31. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011;57:833-40.
32. Rice J, Roberts H, Burton J, Pan J, States V, Rai SN, et al. Assay reproducibility in clinical studies of plasma miRNA. PLoS One 2015;10:e0121948.
33. McAlexander MA, Phillips MJ, Witwer KW. Comparison of methods for miRNA extraction from plasma and quantitative recovery of RNA from cerebrospinal fluid. Front Genet 2013;4:83.
34. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010;50:298-301.
35. Channavajjhala SK, Rossato M, Morandini F, Castagna A, Pizzolo F, Bazzoni F, et al. Optimizing the purification and analysis of miRNAs from urinary exosomes. Clin Chem Lab Med 2014;52:345-54.
36. Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C, et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods 2014;11:809-15.
37. Wylie D, Shelton J, Choudhary A, Adai AT. A novel mean-centering method for normalizing microRNA expression from high-throughput RT-qPCR data. BMC Res Notes 2011; 4:555.
38. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008;14:844-52.
39. Sanders I, Holdenrieder S, Walgenbach-Brünagel G, von Ruecker A, Kristiansen G, Müller SC, et al. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol 2012;19:1017-25.
40. Schaefer A, Jung M, Mollenkopf H-J, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010;126:1166-76.
41. Carlsson J, Helenius G, Karlsson M, Lubovac Z, Andrén O, Olsson B, et al. Validation of suitable endogenous control genes for expression studies of miRNA in prostate cancer tissues. Cancer Genet Cytogenet 2010;202:71-5.
42. Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 2014;18:371-90.
43. Sourvinou IS, Markou A, Lianidou ES. Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. J Mol Diagn 2013;15:827-34.
44. Roberts TC, Coenen-Stass AM, Betts CA, Wood MJ. Detection and quantification of extracellular microRNAs in murine biofluids. Biol Proced Online 2014;16:1-15.
45. Srivastava A, Goldberger H, Afzal Z, Suy S, Collins SP, Kumar D. Detection of circulatory microRNAs in prostate cancer. Methods Mol Biol Clifton NJ 2015;1238:523-38.
46. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin 2010;42:363-9.
47. Goto Y, Kurozumi A, Enokida H, Ichikawa T, Seki N. Functional significance of aberrantly expressed microRNAs in prostate cancer. Int J Urol 2015;22:242-52.
48. Fang Y-X, Gao W-Q. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 2014;33: 135-47.
49. Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, et al. miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle Georget Tex 2014;13:227-39.
50. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211-5.
51. Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 2012;7:e33729.
52. Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M, et al. miR-21: an oncomir on strike in prostate cancer. Mol Cancer 2010;9:12.
53. Li T, Li D, Sha JJ, Sun P, Huang YR. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 2009;383:280-5.
54. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. MiR-34a attenuates paclitaxel resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010;70:1501-12.
55. Verdoodt B, Neid M, Vogt M, Kuhn V, Liffers ST, Palisaar RJ, et al. MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol 2013;43:307-14.
56. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
57. Gregory PA, Bert AG, Paterson EL. The miR-200 family and miR- 205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
58. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucl Acids Res 2005;33:6566-78.
59. Ren D, Wang M, Guo W, Huang S, Wang Z, Zhao X, et al. Double-negative feedback loop between ZEB2 and miR- 145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells. Cell Tissue Res 2014;358:763-78.
60. Coppola V, Musumeci M, Patrizii M, Cannistraci A, Addario A, Maugeri-Saccà M, et al. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. Oncogene 2013;32:1843-53.
61. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON. Basal epitelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci USA 2010;107:2610-5.
62. Reis ST, Pontes-Junior J, Antunesnes AA, Dall Oglio MF, Dip N, Passerotti CC, et al. miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol 2012;12:14.
63. Wang L, Song G, Tan W, Qi M, Zhang L, Chan J, et al. miR-573 inhibits prostate cancer metastasis by regulating epithelialmesenchymal transition. Oncotarget 2015;6:35978-90.
64. ChunJiao S, Huan C, ChaoYang X, GuoMei R. Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer. IUBMB Life 2014;66:379-86.
65. Ayub SG, Kaul D, Ayub T. Microdissecting the role of micro- RNAs in the pathogenesis of prostate cancer. Cancer Genet 2015;208:289-302.
66. Goto Y, Kojima S, Nishikawa R, Kurozumi A, Kato M, Enokida H, et al. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. Br J Cancer 2015;113:1055-65.
67. Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, et al. MiR- 221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 2014;33:2790-800.
68. Yang X, Yang Y, Gan R, Zhao L, Li W, Zhou H, et al. Downregulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. PLoS One 2014;9:e98833.
69. Ottman R, Nguyen C, Lorch R, Chakrabarti R. MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance. Mol Cancer 2014;13:1.
70. Ekimler S, Sahin K. Computational methods for microRNA target prediction. Genes (Basel) 2014;5:671-83.
71. Deng JH, Deng Q, Kuo CH, Delaney SW, Ying SY. MiRNA targets of prostate cancer. Methods Mol Biol 2013;936:357-69.
72. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500.
73. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115: 787-98.
74. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, et al. A combined computational-experimental approach predicts human microRNA targets. Genes Dev 2004;18:1165-78.
75. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006;126:1203-17.
76. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004;10:1507-17.
77. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2004;2:e363.
78. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-9.
79. Kanehisa M. The KEGG database. Novartis Found Symp 2002;247:91-101.
80. Baglioni M, Russo F, Geraci F, Rizzo M, Rainaldi G, Pellegrini M. A new method for discovering disease-specific MiRNA-target regulatory networks. PLoS One 2015;10:e0122473.
81. Zhang W, Zang J, Jing X, Sun Z, Yan W, Yang D, et al. Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer. J Transl Med 2014;12:66.
82. Feng J, Huang C, Diao X, Fan M, Wang P, Xiao Y, et al. Screening biomarkers of prostate cancer by integrating microRNA and mRNA microarrays. Genet Test Mol Biomarkers 2013;17: 807-13.
83. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-61.
84. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67:6130-5.
85. Carlsson J, Davidsson S, Helenius G, Karlsson M, Lubovac Z, Andrén O, et al. A miRNA expression signature that separates between normal and malignant prostate tissues. Cancer Cell Int 2011;11:14.
86. Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, et al. MicroRNA profiling in prostate cancer-the diagnostic potential of urinary miR-205 and miR-214. PLoS One 2013;8:e76994.
87. Hellwinkel OJ, Sellier C, Sylvester Y-M, Brase JC, Isbarn H, Erbersdobler A, et al. A cancer-indicative microRNA pattern in normal prostate tissue. Int J Mol Sci 2013;14:5239-49.
88. Sapre N, Hong MK, Macintyre G, Lewis H, Kowalczyk A, Costello AJ, et al. Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. PLoS One 2014;9:e91729.
89. Chen Z-H, Zhang G-L, Li H-R, Luo J-D, Li Z-X, Chen G-M, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 2012;72:1443-52.
90. Srivastava A, Goldberger H, Dimtchev A, Marian C, Soldin O, Li X, et al. Circulatory miR-628-5p is downregulated in prostate cancer patients. Tumour Biol 2014;35:4867-73.
91. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011;71: 550-60.
92. Nguyen HC, Xie W, Yang M, Hsieh C-L, Drouin S, Lee G-S, et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013;73:346-54.
93. Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancerassociated hypoxia. PLoS One 2013;8:e69239.
94. Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang Y, Helgason CD, et al. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int J Mol Sci 2013;14:7757-70.
95. Mihelich BL, Maranville JC, Nolley R, Peehl DM, Nonn L. Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS One 2015;10:e0124245.
96. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 2012;72:1469-77.
97. Li M, Rai AJ, Joel de Castro G, Zeringer E, Barta T, Magdaleno S, et al. An optimized procedure for exosome isolation and analysis using serum samples: application to cancer biomarker discovery. Methods 2015;87:26-30.
98. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012;106:768-74.
99. Palisaar JR, Noldus J, Löppenberg B, von Bodman C, Sommerer F, Eggert T. Comprehensive report on prostate cancer misclassification by 16 currently used low-risk and active surveillance criteria. BJU Int 2012;110:E172-81.
100. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, et al. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One 2014;9:e98597.
101. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011;128:608-16.
102. Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, et al. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 2014;110:2462-71.
103. Haldrup C, Kosaka N, Ochiya T, Borre M, Høyer S, Orntoft TF, et al. Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug Deliv Transl Res 2014;4:19-30.
104. Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 2015;67:33-41.
105. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011;71:326-31.
106. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 2011;32:583-8.
107. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Müller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011;77:1265.e9-16.
108. Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 2011;9:39-45.
109. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 2012;131:652-61.
110. Westermann AM, Schmidt D, Holdenrieder S, Moritz R, Semjonow A, Schmidt M, et al. Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study. Anticancer Res 2014;34:665-9.
111. Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, et al. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget 2014;5:824-40.
112. Santos JI, Teixeira AL, Dias F, Maurício J, Lobo F, Morais A, et al. Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies. Tumour Biol 2014;35:7105-13.
113. Kotb S, Mosharafa A, Essawi M, Hassan H, Meshref A, Morsy A. Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer. Tumour Biol 2014;35:12613-7.
114. Kelly BD, Miller N, Sweeney KJ, Durkan GC, Rogers E, Walsh K, et al. A circulating microRNA signature as a biomarker for prostate cancer in a high risk group. J Clin Med 2015;4:1369-79.
115. Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T, et al. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol 2015;34:189-200.
116. Huang W, Kang XL, Cen S, Wang Y, Chen X. High-level expression of microRNA-21 in peripheral blood mononuclear cells is a diagnostic and prognostic marker in prostate cancer. Genet Test Mol Biomarkers 2015;19:469-75.
117. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
118. Mlcochova H, Hezova R, Meli AC, Slaby O. Urinary MicroRNAs as a new class of noninvasive biomarkers in oncology, nephrology, and cardiology. Methods Mol Biol 2015;1218:439-63.
119. Alvarez ML, Khosroheidari M, Kanchi Ravi R, DiStefano JK. Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int 2012;82:1024-32.
120. Barutta F, Tricarico M, Corbelli A, Annaratone L, Pinach S, Grimaldi S, et al. Urinary exosomal microRNAs in incipient diabetic nephropathy. PLoS One 2013;8:e73798.
121. Ahumada-Tamayo S, Saavedra-Briones D, Cantellano- Orozco M, Salido-Guadarrama A, Rodríguez-Dorantes M, Urdiales-Ortiz A, et al. MicroRNA determination in urine for prostate cancer detection in Mexican patients at the Hospital General "Dr.Manuel Gea González". Rev Mex Urol 2011;71: 213-7.
122. Korzeniewski N, Tosev G, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S. Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urol Oncol 2015;33:16. e17-22.
123. Corcoran C, Rani S, O'Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate 2014;74:1320-34.
124. Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer 2014;5:182-91.
125. Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masiá E, Casanova J, et al. Identification of miR-187 and miR- 182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol 2014;192:252-9.
126. Stephan C, Jung M, Rabenhorst S, Kilic E, Jung K. Urinary miR- 183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue. Clin Chem Lab Med 2015;53:1109-18.
127. Egidi MG, Guelfi G, Cochetti G, Poli G, Barillaro F, Zampini D, et al. Characterization of kallireins and microRNAs in urine sediment for the discrimination of prostate cancer from benign prostatic hyperplasia. J Cancer Sci Ther 2015;7:130-6.
128. Yun SJ, Jeong P, Kang HW, Kim Y-H, Kim E-A, Yan C, et al. Urinary microRNAs of prostate cancer: virus-encoded hsv1-miRH18 and hsv2-miR-H9-5p could be valuable diagnostic markers. Int Neurourol J 2015;19:74-84.